Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (61-70 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology and Therapy|March 19, 2020
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal TrialRoy Fleischmann, Daniel E Furst, Erin Connolly-Strong, et al.
Rheumatology (Oxford, England)|June 8, 2014
Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritisRoy Fleischmann, Andrew S Koenig, Annette Szumski, et al.
The Journal of Rheumatology|December 7, 2005
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst, Roy Fleischmann, Elliott Kopp, et al.
Arthritis Research & Therapy|November 12, 2019
Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trialsJosef Smolen, Roy Fleischmann, Daniel Aletaha, et al.
Rheumatology and Therapy|February 23, 2018
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid ArthritisStanley Cohen, Jeffrey R Curtis, Ryan DeMasi, et al.
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
RMD Open|October 27, 2017
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritisRoy Fleischmann, Jahangir Alam, Vipin Arora, et al.
The Journal of Rheumatology|April 17, 2004
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJohn Tesser, Roy Fleischmann, Robin Dore, et al.
RMD Open|February 14, 2018
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studiesRoy Fleischmann, Jürgen Wollenhaupt, Liza Takiya, et al.
Arthritis and Rheumatism|December 1, 2011
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patientsMikkel Østergaard, Paul Emery, Philip G Conaghan, et al.
Pageof 19

Showing results (61-70 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology and Therapy|March 19, 2020
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal TrialRoy Fleischmann, Daniel E Furst, Erin Connolly-Strong, et al.
Rheumatology (Oxford, England)|June 8, 2014
Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritisRoy Fleischmann, Andrew S Koenig, Annette Szumski, et al.
The Journal of Rheumatology|December 7, 2005
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst, Roy Fleischmann, Elliott Kopp, et al.
Arthritis Research & Therapy|November 12, 2019
Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trialsJosef Smolen, Roy Fleischmann, Daniel Aletaha, et al.
Rheumatology and Therapy|February 23, 2018
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid ArthritisStanley Cohen, Jeffrey R Curtis, Ryan DeMasi, et al.
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
RMD Open|October 27, 2017
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritisRoy Fleischmann, Jahangir Alam, Vipin Arora, et al.
The Journal of Rheumatology|April 17, 2004
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJohn Tesser, Roy Fleischmann, Robin Dore, et al.
RMD Open|February 14, 2018
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studiesRoy Fleischmann, Jürgen Wollenhaupt, Liza Takiya, et al.
Arthritis and Rheumatism|December 1, 2011
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patientsMikkel Østergaard, Paul Emery, Philip G Conaghan, et al.
Pageof 19